Paxmedica to present at the benchmark company's upcoming discovery one-on-one investor conference

Tarrytown, ny, nov. 22, 2022 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“apt”) for the treatment of disorders with intractable neurologic symptoms, today announced it will be presenting at the benchmark company's 11th annual discovery one-on-one investor conference to be held thursday, december 1st, 2022 at the new york athletic club in new york city.
PXMD Ratings Summary
PXMD Quant Ranking